I’ve heard of Hirschsprung’s Disease as an academically interesting instance of a developmental failure of nerve migration, but you really must read about the human cost of the disease — innocent little babies (and their parents) should never have to suffer this much. Chris Chatham is spreading the word about an expensive nutritional product, Omegaven, that has the potential to alleviate one symptom — liver failure due to the need for sustained IV feeding — and the idea is to encourage clinical testing so the treatment can be more widely used and supported by insurance companies. Let’s raise the profile of this work and try to get some media attention; reducing the need for infant liver transplants sounds like a worthy cause.